in Vivo TICE (TransIntestinal Cholesterol Excretion) (in vivoTICE)

Nantes University Hospital (NUH)

Status: Unknown

Conditions: Occlusion of Bile Duct With an External Bile Diversion.

Treatments: Other: Intravenous injection of deuterated cholesterol diluted in intralipid 20%

Study type: Interventional

Funder types: Other

Identifiers

NCT01958216

RC11_0008

Details and patient eligibility

About

So far, the liver has been the main target for cholesterol elimination. However, several recent studies performed in mice have described a new route of cholesterol excretion, the Trans-Intestinal Cholesterol Excretion or TICE. TICE allows direct elimination of plasma cholesterol in the feces directly via the intestine. Until now, only indirect evidence suggests that TICE is also active in humans, the goal of this proof of concept study is to provide the first proof of its existence in humans by using stable isotopes in patients with bile duct diversion.

Enrollment: 5 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• External bile duct diverted patients

Exclusion criteria

• Inflammatory bowel disease
• Aphagia
• Renal or hepatocellular insufficiency
• Primary intestinal tumor
• Cholangitis or severe sepsis
• Acute or chronic diarrhea

Trial design

5 participants in 1 patient group

Trans-intestinal cholesterol excretion in vivo

Other group

Description:

Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients

Treatment:

Other: Intravenous injection of deuterated cholesterol diluted in intralipid 20%